Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control

NCT03386344 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
376
Enrollment
INDUSTRY
Sponsor class

Stopped Study terminated prematurely for financial reasons and Covid-19 pandemic.

Conditions

Interventions

Sponsor

Lexicon Pharmaceuticals

Collaborators